Overview

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Status:
Not yet recruiting
Trial end date:
2026-01-30
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.
Phase:
Phase 3
Details
Lead Sponsor:
KalVista Pharmaceuticals, Ltd.